NF-κB can be aberrantly activated in cancer by chemotherapeutic agents and ionizing radiation, response to stress, and induced cell death, leading to treatment-induced resistance of tumor cells (Jung and Dritschilo, 2001; Garg et al., 2003; Sampepajung et al., 2021). Here, NFKB1 is linked to cancer.